Drug Profile
Research programme: protein therapeutics - Navigo Proteins GmbH
Alternative Names: Human binding proteins research programme - Navigo Proteins; proNGF SPR14; Protein therapeutics research programme - Navigo Proteins; SPR-1401; SPVF 2805-10; SPVF 2805-30; SPVF 2805-40; SPVF-2801; SPVF-2801-10; SPVF-2801-30; SPWF-1501; SPWF-2801; SPWF-2802; SPWF-2803Latest Information Update: 25 Sep 2017
Price :
$50
*
At a glance
- Originator Scil Proteins
- Developer Anabasis Pharma; Navigo Proteins
- Class Nerve growth factors; Recombinant proteins
- Mechanism of Action Immunomodulators; Neuron stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer; Inflammation
Highest Development Phases
- No development reported Eye disorders; Inflammation; Solid tumours
- Discontinued Multiple sclerosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in Germany
- 16 Jul 2016 No recent reports of development identified for research development in Eye-disorders in Italy
- 16 Jul 2016 No recent reports of development identified for research development in Inflammation in Germany